Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drainage technique may reduce pancreatitis risk after tumor surgery

NCT ID NCT07446543

Disease control Sponsor: Cui Xiaobing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a gentle suction tube (negative-pressure drainage) is better than placing a small plastic tube (stent) in the pancreas to prevent pancreatitis after removing tumors from the duodenum. About 132 adults with early-stage tumors will be randomly assigned to one of the two methods. The main goal is to see which approach leads to fewer cases of pancreatitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 75 years 2. Preoperative diagnosis of duodenal papillary adenoma or early-stage adenocarcinoma (≤T1a) 3. Scheduled to undergo endoscopic papillectomy Exclusion Criteria: 1. Preoperative diagnosis suggestive of adenocarcinoma ≥T1b stage. 2. Preoperative imaging indicating intraductal extension into the pancreatic or bile duct ≥20 mm. 3. Lesion diameter \>40 mm, location adjacent to a duodenal diverticulum, or other anatomical or technical factors deemed unsuitable for endoscopic resection. 4. Known familial adenomatous polyposis (FAP). 5. Severe cardiopulmonary disease precluding tolerance of anesthesia or endoscopic procedures. 6. Coagulopathy or bleeding disorders. 7. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ampulla of vater neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ampulla of vater adenocarcinoma ampulla of vater neoplasm carcinoma of the ampulla of vater papillary adenoma periampullary adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ampulla of vater neoplasms Ampullary adenoma Ampullary carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.